Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 45,910 shares, an increase of 55.9% from the July 15th total of 29,440 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average trading volume of 25,260 shares, the short-interest ratio is presently 1.8 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.00.

Institutional Trading of Barinthus Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rangeley Capital LLC grew its position in shares of Barinthus Biotherapeutics by 88.8% in the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after acquiring an additional 75,024 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Barinthus Biotherapeutics by 115.8% in the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after purchasing an additional 76,800 shares during the period. Finally, Baird Financial Group Inc. lifted its stake in Barinthus Biotherapeutics by 108.2% in the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after purchasing an additional 100,000 shares during the last quarter. 25.20% of the stock is owned by institutional investors.

Barinthus Biotherapeutics Stock Up 4.5%

BRNS stock opened at $0.62 on Wednesday. The business has a 50 day moving average price of $0.63 and a two-hundred day moving average price of $0.63. The company has a market cap of $25.33 million, a price-to-earnings ratio of -0.60 and a beta of -0.39. Barinthus Biotherapeutics has a twelve month low of $0.51 and a twelve month high of $1.83.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.